论文部分内容阅读
肾小管间质纤维化(RIF)是各种原因引起的慢性肾脏病(CKD)的共同通路和主要病理特征,是判断肾脏疾病预后的最重要的组织学指标。RIF的严重程度与肾衰竭密切相关。肝细胞生长因子(HGF)可以通过不同途径抑制RIF进程。HGF被认为可作为判断RIF的发生、发展和CKD预后的重要指标,日益受到人们的关注。该文就HGF抑制肾纤维化形成的分子机制的研究进展予以综述,揭示HGF在治疗肾纤维化方面所具有的前景。
Tubulointerstitial fibrosis (RIF) is a common pathway and major pathological features of chronic kidney disease (CKD) caused by various causes and is the most important histological index for judging the prognosis of renal diseases. The severity of RIF is closely related to renal failure. Hepatocyte growth factor (HGF) can inhibit the RIF process through different pathways. HGF is considered as an important index to judge the occurrence and development of RIF and the prognosis of CKD, which attracts more and more attention. This review summarizes the molecular mechanisms of HGF inhibiting renal fibrosis and reveals the potential of HGF in the treatment of renal fibrosis.